SARS-CoV-2 Reactivity with BioFire Respiratory Panels
Bioinformatics for the SARS-CoV-2 virus is expanding at a rapid rate since the emergence of the virus in human infection in late 2019. Thousands of viral whole genome sequences are being evaluated and submitted to public and private databases on a weekly basis.
BioFire continues to monitor these new sequences and is performing regular in silico analyses of the SARS-CoV-2 assays in the BioFire RP2.1 Panel family of products (the BioFire RP2.1 Panel, the BioFire® Respiratory 2.1 plus Panel**, and the BioFire RP2.1-EZ Panel [EUA]) in accordance with the FDA’s policy for evaluating the impact of viral mutations on COVID-19 tests.
Please consult the BioFire Respiratory Panels SARS-CoV-2 Reactivity Technical Note for the latest reactivity updates with emerging variants.